Cardioprotection with postconditioning: Loss of efficacy in murine models of type-2 and type-1 diabetes

Antioxidants and Redox Signaling

Volumn 14, Issue 5, 2011, Pages 781-790

  Przyklenk, Karin ^a,b   Maynard, Michelle ^a   Greiner, Dale L ^a   Whittaker, Peter ^a,b  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; MITOGEN ACTIVATED PROTEIN KINASE 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; CELL TRANSPLANTATION; CONTROLLED STUDY; GLUCOSE BLOOD LEVEL; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART PROTECTION; INSULIN DEPENDENT DIABETES MELLITUS; ISCHEMIC POSTCONDITIONING; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET CELL; PRIORITY JOURNAL; REPERFUSION INJURY; REVIEW;

ANIMALS; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DISEASE MODELS, ANIMAL; HEART; ISCHEMIC POSTCONDITIONING; MICE; MICE, INBRED C57BL; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION INJURY; RANDOM ALLOCATION; RATS;

MURINAE; MUS;

EID: 79551672046     PISSN: 15230864     EISSN: None     Source Type: Journal    
DOI: 10.1089/ars.2010.3343     Document Type: Review

References (50)

1. Boengler K, Buechert A, Heinen Y, Roeskes C, Hilfiker-Kleiner D, Heusch G, and Schulz R. Cardioprotection by ischemic postconditioning is lost in aged and STAT3-deficient mice. Circ Res 102: 131-135, 2008.
2. Bouhidel O, Pons S, Souktani R, Zini R, Berdeaux A, and Ghaleh B. Myocardial ischemic postconditioning against ischemia-reperfusion is impaired in ob=ob mice. Am J Physiol Heart Circ Physiol 295: H1580-H1586, 2008.
3. Bugger H and Abel ED. Rodent models of diabetic cardiomyopathy. Dis Model Mech 2: 454-466, 2009.
4. Camps M, Nichols A, and Arkinstall S. Dual specificity phosphatases: a gene family for control of MAP kinase function. FASEB J 14: 6-16, 2000.
5. Carley AN and Severson DL. What are the biochemical mechanisms responsible for enhanced fatty acid utilization by perfused hearts from type 2 diabetic db=db mice? Cardiovasc Drugs Ther 22: 83-89, 2008.
6. Darling CE, Jiang R, Maynard M, Whittaker P, Vinten-Johansen J, and Przyklenk K. Postconditioning via stuttering reperfusion limits myocardial infarct size in rabbit hearts: role of ERK1=2. Am J Physiol Heart Circ Physiol 289: H1618-H1626, 2005.
7. Darling CE, Solari PB, Smith CS, Furman MI, and Przyklenk K. "Postconditioning" the human heart: multiple balloon inflations during primary angioplasty may confer cardioprotection. Basic Res Cardiol 102: 274-278, 2007.
8. Di Filippo C, Marfella R, Cuzzocrea S, Piegari E, Petronella P, Giugliano D, Rossi F, and DAmico M. Hyperglycemia in streptozotocin-induced diabetic rat increases infarct size associated with low levels ofmyocardial HO-1 during ischemia= reperfusion. Diabetes 54: 803-810, 2005.
9. Dickinson RJ and Keyse SM. Diverse physiological functions for dual-specificity MAP kinase phosphatases. J Cell Sci 119: 4607-4615, 2006.
10. Ferdinandy P, Schulz R, and Baxter GF. Interaction of cardiovascular risk factors with myocardial ischemia= reperfusion injury, preconditioning, and postconditioning. Pharmacol Rev 59: 418-458, 2007.
11. Gambert S, Vergely C, Filomenko R, Moreau D, Bettaieb A, Opie LH, and Rochette L. Adverse effects of free fatty acid associated with increased oxidative stress in postischemic isolated rat hearts. Mol Cell Biochem 283: 147-152, 2006.
12. Granfeldt A, Lefer DJ, and Vinten-Johansen J. Protective ischaemia in patients: preconditioning and postconditioning. Cardiovasc Res 83: 234-246, 2009.
13. Gross ER, Hsu AK, and Gross GJ. Diabetes abolishes morphine-induced cardioprotection via multiple pathways upstream of glycogen synthase kinase-3{beta}. Diabetes 56: 127-136, 2007.
14. Hayashi K, Kojima R, and Ito M. Strain differences in the diabetogenic activity of streptozotocin in mice. Biol Pharm Bull 29: 1110-1119, 2006.
15. Huhn R, Heinen A, Hollmann MW, Schlack W, Preckel B, and Weber NC. Cyclosporine A administered during reperfusion fails to restore cardioprotection in prediabetic Zucker obese rats in vivo. Nutr Metab Cardiovasc Dis 2009 [Epub ahead of print].
16. Huhn R, Heinen A, Weber NC, Hollmann MW, Schlack W, and Preckel B. Hyperglycaemia blocks sevoflurane-induced postconditioning in the rat heart in vivo: cardioprotection can be restored by blocking the mitochondrial permeability transition pore. Br J Anaesth 100: 465-471, 2008.
17. Huhn R, Heinen A, Weber NC, Kerindongo RP, Oei GT, Hollmann MW, Schlack W, and Preckel B. Helium-induced early preconditioning and postconditioning are abolished in obese Zucker rats in vivo. J Pharmacol Exp Ther 329: 600-607, 2009.
18. Kersten JR, Toller WG, Gross ER, Pagel PS, and Warltier DC. Diabetes abolishes ischemic preconditioning: role of glucose, insulin, and osmolality. Am J Physiol Heart Circ Physiol 278: H1218-H1224, 2000.
19. Kersten JR, Toller WG, Tessmer JP, Pagel PS, and Warltier DC. Hyperglycemia reduces coronary collateral blood flow through a nitric oxide-mediated mechanism. Am J Physiol Heart Circ Physiol 281: H2097-H2104, 2001.
20. Kin H, Zatta AJ, Lofye MT, Amerson BS, Halkos ME, Kerendi F, Zhao Z-Q, Guyton RA, Headrick JP, and Vinten-Johansen J. Postconditioning reduces infarct size via adenosine receptor activation by endogenous adenosine. Cardiovasc Res 67: 124-133, 2005.
21. Kristiansen SB, Lofgren B, Stottrup NB, Khatir D, Nielsen-Kudsk JE, Nielsen TT, Botker HE, and Flyvbjerg A. Ischaemic preconditioning does not protect the heart in obese and lean animal models of type 2 diabetes. Diabetologia 47: 1716-1721, 2004.
22. Lacerda L, Somers S, Opie LH, and Lecour S. Ischaemic postconditioning protects against reperfusion injury via the SAFE pathway. Cardiovasc Res 84: 201-208, 2009.
23. Lecour S. Activation of the protective Survivor Activating Factor Enhancement (SAFE) pathway against reperfusion injury: does it go beyond the RISK pathway? J Mol Cell Cardiol 47: 32-40, 2009.
24. Liu Y, Thornton JD, Cohen MV, Downey JM, and Schaffer SW. Streptozotocin-induced non-insulin-dependent diabetes protects the heart from infarction. Circulation 88: 1273-1278, 1993.
25. Lloyd-Jones D, Adams RJ, Brown TM, Carnethon M, Dai S, De Simone G, Ferguson TB, Ford E, Furie K, Gillespie C, Go A, Greenlund K, Haase N, Hailpern S, Ho PM, Howard V, Kissela B, Kittner S, Lackland D, Lisabeth L, Marelli A, McDermott MM, Meigs J, Mozaffarian D, Mussolino M, Nichol G, Roger VL, Rosamond W, Sacco R, Sorlie P, Stafford R, Thom T, Wasserthiel-Smoller S, Wong ND, and Wylie-Rosett J. Heart disease and stroke statistics-2010 update: a report from the american heart association. Circulation 121: e46-e215, 2010.
26. Marfella R, Di Filippo C, Esposito K, Nappo F, Piegari E, Cuzzocrea S, Berrino L, Rossi F, Giugliano D, and DAmico M. Absence of inducible nitric oxide synthase reduces myocardial damage during ischemia reperfusion in streptozotocin-induced hyperglycemic mice. Diabetes 53: 454-462, 2004.
27. Mewton N, Ivanes F, Cour M, and Ovize M. Postconditioning: from experimental proof to clinical concept. Dis Model Mech 3: 39-44, 2010.
28. Olson AK, Protheroe KN, Segar JL, and Scholz TD. Mitogenactivated protein kinase activation and regulation in the pressure-loaded fetal ovine heart. Am J Physiol 290: H1587-H1595, 2006.
29. Penna C, Tullio F, Merlino A, Moro F, Raimondo S, Rastaldo R, Perrelli MG, Mancardi D, and Pagliaro P. Postconditioning cardioprotection against infarct size and post-ischemic systolic dysfunction is influenced by gender. Basic Res Cardiol 104: 390-402, 2009.
30. Przyklenk K, Maynard M, Darling CE, and Whittaker P. Aging mouse hearts are refractory to infarct size reduction with post-conditioning. J Am Coll Cardiol 51: 1393-1398, 2008.
31. Przyklenk K, Maynard M, and Whittaker P. First molecular evidence that inositol trisphosphate signaling contributes to infarct size reduction with preconditioning. Am J Physiol 291: H2008-H2012, 2006.
32. Raphael J, Gozal Y, Navot N, and Zuo Z. Hyperglycemia inhibits anesthetic-induced postconditioning in the rabbit heart via modulation of phosphatidylinositol-3-kinase=Akt and endothelial nitric oxide synthase signaling. J Cardiovasc Pharmacol 55: 348-357, 2010.
33. Ravingerova T, Neckar J, and Kolar F. Ischemic tolerance of rat hearts in acute and chronic phases of experimental diabetes. Mol Cell Biochem 249: 167-174, 2003.
34. Rodriguez-Sinovas A, Cabestrero A, Garcia del Blanco B, Inserte J, Garcia A, and Garcia-Dorado D. Intracoronary acid infusion as an alternative to ischemic postconditioning in pigs. Basic Res Cardiol 104: 761-771, 2009.
35. Ryan JG. Cost and policy implications from the increasing prevalence of obesity and diabetes mellitus. Gend Med 6 Suppl 1: 86-108, 2009.
36. Seung E, Iwakoshi N, Woda BA, Markees TG, Mordes JP, Rossini AA, and Greiner DL. Allogeneic hematopoietic chimerism in mice treated with sublethal myeloablation and anti-CD154 antibody: absence of graft-versus-host disease, induction of skin allograft tolerance, and prevention of recurrent autoimmunity in islet-allografted NOD=Lt mice. Blood 95: 2175-2182, 2000.
37. Skyschally A, van Caster P, Boengler K, Gres P, Musiolik J, Schilawa D, Schulz R, and Heusch G. Ischemic postconditioning in pigs: no causal role for RISK activation. Circ Res 104: 15-18, 2009.
38. Staat P, Rioufol G, Piot C, Cottin Y, Cung TT, LHuillier I, Aupetit JF, Bonnefoy E, Finet G, Andre-Fouet X, and Ovize M. Postconditioning the human heart. Circulation 112: 2143-2148, 2005.
39. Tamura S, Hanada M, Ohnishi M, Katsura K, Sasaki M, and Kobayashi T. Regulation of stress-activated protein kinase signaling pathways by protein phosphatases. Eur J Biochem 269: 1060-1066, 2002.
40. Thibault H, Piot C, Staat P, Bontemps L, Sportouch C, Rioufol G, Cung TT, Bonnefoy E, Angoulvant D, Aupetit JF, Finet G, Andre-Fouet X, Macia JC, Raczka F, Rossi R, Itti R, Kirkorian G, Derumeaux G, and Ovize M. Long-term benefit of postconditioning. Circulation 117: 1037-1044, 2008.
41. Tosaki A, Engelman DT, Engelman RM, and Das DK. The evolution of diabetic response to ischemia=reperfusion and preconditioning in isolated working rat hearts. Cardiovasc Res 31: 526-536, 1996.
42. Tsang A, Hausenloy DJ, Mocanu MM, Carr RD, and Yellon DM. Preconditioning the diabetic heart: the importance of Akt phosphorylation. Diabetes 54: 2360-2364, 2005.
43. Tsang A, Hausenloy DJ, Mocanu MM, and Yellon DM. Postconditioning: a form of "modified reperfusion" protects the myocardium by activating the phosphatidylinositol 3-kinase-Akt pathway. Circ Res 95: 230-232, 2004.
44. Vinten-Johansen J, Granfeldt A, Mykytenko J, Undyala VV, Dong Y, and Przyklenk K. The multidimensional physiological responses to postconditioning. Antioxid Redox Signal 14: 791-810, 2011.
45. Vinten-Johansen J, Zhao ZQ, Zatta AJ, Kin H, Halkos ME, and Kerendi F. Postconditioning-a new link in natures armor against myocardial ischemia-reperfusion injury. Basic Res Cardiol 100: 295-310, 2005.
46. Wagner C, Kloeting I, Strasser RH, and Weinbrenner C. Cardioprotection by postconditioning is lost in WOKW rats with metabolic syndrome: role of glycogen synthase kinase 3beta. J Cardiovasc Pharmacol 52: 430-437, 2008.
47. Yang XC, Liu Y, Wang LF, Cui L, Wang T, Ge YG, Wang HS, Li WM, Xu L, Ni ZH, Liu SH, Zhang L, Jia HM, Vinten-Johansen J, and Zhao ZQ. Reduction in myocardial infarct size by postconditioning in patients after percutaneous coronary intervention. J Invasive Cardiol 19: 424-430, 2007.
48. Yang XM, Philipp S, Downey JM, and Cohen MV. Postconditionings protection is not dependent on circulating blood factors or cells but involves adenosine receptors and requires PI3-kinase and guanylyl cyclase activation. Basic Res Cardiol 100: 57-63, 2005.
49. Yang XM, Proctor JB, Cui L, Krieg T, Downey JM, and Cohen MV. Multiple, brief coronary occlusions during early reperfusion protect rabbit hearts by targeting cell signaling pathways. J Am Coll Cardiol 44: 1103-1110, 2004.
50. Zhao ZQ, Corvera JS, Halkos ME, Kerendi F, Wang NP, Guyton RA, and Vinten-Johansen J. Inhibition of myocardial injury by ischemic postconditioning during reperfusion: comparison with ischemic preconditioning. Am J Physiol 285: H579-H588, 2003.